Learn More
511 Background: Based on interim results of the prospective, randomized, multicenter Chemo N0 trial and an EORTC pooled analysis (n = 8,377), ASCO and AGO guidelines recommend invasion markers(More)
AIM Final 10-year analysis of the prospective randomised Chemo-N0 trial is presented. Based on the Chemo-N0 interim results and an European Organisation for Research and Treatment of Cancer (EORTC)(More)
CD66a, also known as biliary glycoprotein (BGP), is a member of the carcinoembryonic antigen (CEA) family and the human homologue of the rat cell-CAM. There is evidence that aberrant expression or(More)